Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?

被引：1
|
作者：
Zaffuto, Emanuele [1 ,2 ]
Karakiewicz, Pierre I. [2 ]
Capitanio, Umberto [1 ]
机构：
[1] IRCCS Osped San Raffaele, Urol Res Inst, Unit Urol, Div Oncol, Milan, Italy
[2] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2016年 / 4卷 / 15期
关键词：
CELL CARCINOMA; INTERFERON ALPHA-2A; SURVIVAL; INTERLEUKIN-2; SORAFENIB; AGENTS;
D O I：
10.21037/atm.2016.06.25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] First-line therapy for metastatic gastric cancer - what treatment for which patient?
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 127 - 128
  • [42] Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors
    Basappa, Naveen S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (11-12): : S242 - S244
  • [43] Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions
    Wubben, Thomas J.
    Johnson, Mark W.
    Sohn, Elliott H.
    Peairs, James J.
    Kay, Christine N.
    Kim, Stephen J.
    Gardner, Thomas W.
    Paulus, Yannis M.
    Zacks, David N.
    Steinle, Nathan C.
    Avery, Robert L.
    Berrocal, Maria H.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 204 : 13 - 18
  • [44] Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study
    Cesas, Alvydas
    Urbonas, Vincas
    Tulyte, Skaiste
    Janciauskiene, Rasa
    Liutkauskiene, Sigita
    Grabauskyte, Ingrida
    Gaidamavicius, Ignas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 6979 - 6988
  • [45] Anti-Vascular Endothelial Growth Factor Therapy for Breast Cancer: Can We Pick the Winners?
    Schneider, Bryan P.
    Sledge, George W., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2444 - 2447
  • [46] Synergistic therapeutic strategies and engineered nanoparticles for anti-vascular endothelial growth factor therapy in cancer
    Khafaga, Asmaa F.
    Gaballa, Mohamed M. S.
    Karam, Reham
    Shoulah, Salma A.
    Shamma, Rehab N.
    Khalifa, Norhan E.
    Farrag, Nehal E.
    Noreldin, Ahmed E.
    LIFE SCIENCES, 2024, 341
  • [47] Subfoveal Choroidal Thickness as a Predictor of Treatment Response to Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy
    Kim, Hyesun
    Park, Hyun Ju
    Lee, SungChul
    Lee, Christopher Seungkyu
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [48] Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy
    Kim, Hyesun
    Lee, Sung Chul
    Kwon, Kye Yoon
    Lee, Ji Hwan
    Koh, Hyoung Jun
    Byeon, Suk Ho
    Kim, Sung Soo
    Kim, Min
    Lee, Christopher Seungkyu
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 254 (08) : 1497 - 1503
  • [49] Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy
    Hyesun Kim
    Sung Chul Lee
    Kye Yoon Kwon
    Ji Hwan Lee
    Hyoung Jun Koh
    Suk Ho Byeon
    Sung Soo Kim
    Min Kim
    Christopher Seungkyu Lee
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 : 1497 - 1503
  • [50] Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Tachibana, Hidekazu
    Yoshida, Kazuhiko
    Omae, Kenji
    Iizuka, Junpei
    Kobayashi, Hirohito
    Tanabe, Kazunari
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 559 - 567
12345